This scenario is most likely to exist in cancer patients during chemotherapy, as the anti-cancer drugs are not evenly distributed within the tumor, then cancer cells exposed to lower concentrations of drugs may upregulate ACE2 through this mechanism, and the elevated ACE2 allows the cells to survive by reducing oxidative stress damage caused by ROS. Here, ACE2 is linked to cancer.